Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.

ROCKVILLE, MD – There is a need for the scientific community to explore the use of additional strength biowaivers for modified release (MR) drugs given the increasing market demand for these “patient ...